Lonza is a global leader in contract development and manufacturing services with strong R&D capabilities and world-class facilities across five continents. In 2020, Lonza supported more than 820 pre-clinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced 230 billion capsules.

Founded in 1897 in Gampel, Switzerland, Lonza is a preferred global partner to the pharma, biotech and nutrition industries. With approximately 14,000 full-time employees, the company is led by Pierre-Alain Ruffieux, CEO, and Albert Baehny, Chairman of the Board of Directors of Lonza Group Ltd.

Lonza works to prevent illness and enable a healthier world by supporting its customers to deliver new and innovative medicines that help treat a wide range of diseases. Lonza's broad capabilities span across biologics, small molecules, bioconjugates, mRNA, and cell and gene technologies. The company manages projects from research, discovery and pre-clinical stages, through to commercialization, from established therapeutics to advanced personalized medicines. Its expertise covers both drug substance and drug product.

Lonza’s contract development and manufacturing services portfolio is recognized for its high-quality services, regulatory track record, strong R&D capabilities, global footprint, innovative technology platforms and extensive experience. In 2020, Lonza supported more than 820 preclinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced 230 billion capsules.